scholarly journals The Progression of Chronic Myeloid Leukemia to Myeloid Sarcoma: A Systematic Review

Cureus ◽  
2022 ◽  
Author(s):  
Hadia Arzoun ◽  
Mirra Srinivasan ◽  
Santhosh Raja Thangaraj ◽  
Siji S Thomas ◽  
Lubna Mohammed
Keyword(s):  
Systematic Review ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Myeloid Sarcoma

PCN63 Systematic Review of Utility Estimates for Health States Associated with Chronic Myeloid Leukemia

2021 ◽  
Vol 24 ◽  
pp. S31
Author(s):  
R. Agrawal ◽  
J. Vieira ◽  
J. Ryan ◽  
D. Thakur ◽  
R. Viana
Keyword(s):  
Systematic Review ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Health States

Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis

2018 ◽  
Vol 131 ◽  
pp. 244-254 ◽  
Author(s):  
Sarah Cargnin ◽  
Gloria Ravegnini ◽  
Simona Soverini ◽  
Sabrina Angelini ◽  
Salvatore Terrazzino
Keyword(s):  
Systematic Review ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Meta Analysis

scholarly journals Chronic phase of chronic myeloid leukemia presenting with myeloid sarcoma in an adolescent

2020 ◽  
Vol 55 (2) ◽  
pp. 112-115
Author(s):  
Hee Jin Lee ◽  
Mi Jin Gu ◽  
Eunjung Kong ◽  
Jae Min Lee
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Chronic Phase ◽  
Myeloid Sarcoma

scholarly journals Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Olga Mulas ◽  
Giovanni Caocci ◽  
Brunella Mola ◽  
Giorgio La Nasa
Keyword(s):  
Systematic Review ◽  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Meta Analysis ◽  
Cardiovascular Complication ◽  
Third Generation ◽  
Pubmed Database

Background: Off-target effects in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) are associated with cardiovascular toxicity. Hypertension represents an important cardiovascular complication and, if not appropriately managed, can contribute to developing thrombotic events. Third-generation TKI ponatinib is associated with hypertension development, and its use is more restricted than in the past. Few data are reported for second-generation TKI, nilotinib, dasatinib, and bosutinib. The aim of this article was to evaluate with a systematic review and meta-analysis the real incidence of hypertension in CML patients treated with second- or third-generation TKI.Methods: The PubMed database, Web of Science, Scopus, and ClinicalTrials.gov were systematically searched for studies published between January 1, 2000, and January 30, 2021; the following terms were entered in the database queries: Cardiovascular, Chronic Myeloid Leukemia, CML, Tyrosine kinases inhibitor, TKI, and Hypertension. The study was carried out according to the Preferred Reporting Items for Systematic and Meta-Analyses (PRISMA) statement.Results: A pooled analysis of hypertension incidence was 10% for all new-generation TKI, with an even higher prevalence with ponatinib (17%). The comparison with the first-generation imatinib confirmed that nilotinib was associated with a significantly increased risk of hypertension (RR 2; 95% CI; 1.39-2.88, I2=0%, z=3.73, p=0.0002). The greatest risk was found with ponatinib (RR 9.21; 95% CI; 2.86-29.66, z=3.72, p=0.0002).Conclusion: Hypertension is a common cardiovascular complication in CML patients treated with second- or third-generation TKI.

Sign in / Sign up

Export Citation Format

Share Document